Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable ( ...

Financial Performance - ZYNLONTA® net sales reached $17.8 million in Q1 2024, a 7% increase from Q4 2023 but a 6% decrease from Q1 2023[3] - Total operating expenses decreased by 25% (adjusted total operating expenses decreased by 16%) compared to Q1 2023[1] - Net loss decreased to $46.6 million in Q1 2024 from $59.4 million in Q1 2023, driven by lower operating expenses[13] - Adjusted net loss was $31.1 million in Q1 2024, compared to $41.8 million in Q1 2023[13] - Total revenue for Q1 2024 was $18.053 million, a decrease of 5% compared to $18.992 million in Q1 2023[27] - Net loss for Q1 2024 was $46.606 million, an improvement from $59.374 million in Q1 2023[27] - Adjusted net loss for Q1 2024 was $31.147 million, compared to $41.759 million in Q1 2023[31] - Adjusted net loss per share for Q1 2024 was $0.38, compared to $0.52 in Q1 2023[31] - Total operating expenses decreased by 25% to $51.666 million in Q1 2024 from $69.202 million in Q1 2023[27] - Adjusted total operating expenses decreased by 16% to $51.508 million in Q1 2024 from $61.128 million in Q1 2023[30] - ZYNLONTA® product revenues decreased to $17.848 million in Q1 2024 from $18.953 million in Q1 2023[27] Cash Position and Runway - Cash and cash equivalents were $234.3 million as of March 31, 2024, with cash runway expected to extend into Q4 2025[8] - Cash and cash equivalents decreased to $234.285 million as of March 31, 2024, from $278.598 million as of December 31, 2023[28] - The company expects its cash runway to extend into the beginning of Q4 2025[24] Research and Development - LOTIS-7 dose escalation completed and expansion initiated in 2L+ DLBCL, with no dose-limiting toxicities observed[3][4] - Initial Phase 2 data from 15 MZL patients showed 13 complete responses (CR) and 1 partial response (PR)[4] - ADCT-601 Phase 1b trial continues enrollment in pancreatic cancer monotherapy arm, with additional data updates expected in H2 2024[5][7] - R&D expenses decreased to $25.7 million in Q1 2024 from $38.4 million in Q1 2023, primarily due to reduced investment in camidanlumab tesirine (Cami)[10] - Research and development expenses decreased to $25.735 million in Q1 2024 from $38.375 million in Q1 2023[27] - Preclinical data on Claudin-6 and NaPi2b targeting ADCs demonstrated potent anti-tumor activity and tolerability[5]

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need Research event featured next-generation ADC platform and t ...

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All patients achieving responses maintained them at the time of data cutoff ZYNLONTA was generally well-tolerated and safety was consistent with known profile Data were presented at Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Scientific Workshop LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ...

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been initiated LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® (lonca ...

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company's novel exatecan-based antibody drug conjugate platform. A live question and answer session will follow the pr ...

ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Results Earnings Conference Call March 13, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Patrick van Berkel - Chief Scientific Officer Jose Carmona - Chief Financial Officer Conference Call Participants Naureen Quibria - Capital One Securities, Inc. Brian Cheng - J.P. Morgan Gregory Renz ...

4Q 2023 Earnings Call Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or ADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be ...

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -119.15%. A quarter ago, it was expected that this company would post a loss of $0.61 per share when it actually produced a loss of $0.58, delivering a surprise of 4.92%.Over the last four quarters, the company has sur ...

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21%1 year-over-year due to portfolio prioritization and operational efficiencies; $278.6M o ...